ClinicalTrials.gg
TerminatedNCT07062952Updated Nov 9, 2026

Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery

An interventional study of Salt substitute in Kidney Tumors, CKD and Salt Substitute, sponsored by Jinling Hospital, China. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Jinling Hospital, China · Not applicable, Interventional, and Prevention

How we know

Why this study was terminated
The study was discontinued following a reassessment of the original protocol, which identified the need for substantial modifications to the study design and implementation. The original study was therefore considered unsuitable for continuation
Updated Nov 9, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Carcinoma, Renal Cell with a site in China — 112 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Enrollment
73rd of 190
93 · median 66
Started
2025
with 35 others
No phase
33 of 235
20 open now
Registered
177th of 235
by date
Lead sponsor
9 of 235
Jinling Hospital, China

Among the 235 studies in Carcinoma, Renal Cell with a site in China, this one is the 73rd largest by enrollment of the 190 interventional ones that give a count, is one of 36 that started in 2025, is one of 33 with no phase, and was the 177th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

112 of the 235 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

This clinical trial is an open-label, randomized controlled study designed to evaluate the efficacyand safety of salt substitutes in protecting renal function after kidney tumor surgery, aiming toprovide dietary renal protection strategies for postoperative kidney tumor patients. lt will alsoassess the feasibility of salt substitute intervention. The primary research questions are:

  1. Does a salt substitute diet significantly improve estimated glomerular filtration rate (eGFR) compared to a regular salt diet in postoperative kidney tumor patients?
  2. What is the safety profile of salt substitute intervention in postoperative kidney tumor patients?
  3. What is the compliance rate among postoperative kidney tumor patients using saltsubstitutes?
  4. ls the salt substitute intervention feasible?

Researchers will compare the intervention group (salt substitute diet) with the control group (regular salt diet) to determine whether salt substitutes effectively improve postoperative eGFR in kidney tumor patients.

Participants will be required to:

  1. Consume salt substitutes or regular salt daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year.
  2. Undergo scheduled baseline assessments at 1, 3, 6, and 12 months post-surgery, with 24-hoururine tests at months 1 and 6 to evaluate compliance.
  3. Receive regular monitoring of blood electrolytes, eGFR, and other renal function indicators.
  4. Document any adverse events or health status changes during the study period.
Read the detailed description

Patients after kidney tumor surgery (radical nephrectomy or partial nephrectomy) experience acute loss of functional nephrons, causing compensatory hyperfunction in remaining nephrons under overload conditions. This manifests as elevated glomerular filtration rate (hyperfiltration), increased plasma flow (hyperperfusion), and heightened capillary transmembrane pressure (hypertension), collectively termed the "three-high glomerular state," significantly increasing risks of Acute Kidney Injury(AKI) and long-term Chronic Kidney Disease(CKD). Chinese populations consume salt far exceeding WHO recommendations, with proven associations to hypertension, stroke, cardiovascular disease, kidney disease, and gastric cancer. High salt intake elevates CKD risk through two pathways: chronic high salt consumption induces hypertension (a key CKD risk factor), and activates renal renin-angiotensin-aldosterone system (RAAS), promoting inflammation, fibrosis, and oxidative stress-induced kidney damage-exacerbating the postoperative "three-high state" and further increasing CKD risk. Additionally, Asian populations frequently carry salt-sensitive genetic variants, where both salt sensitivity and high intake cause mineralocorticoid receptor overactivation, independently amplifying CKD susceptibility. Salt substitutes (potassium-enriched low-sodium salt, primarily NaCl and KCl) reduce sodium content versus regular salt, potentially improving renal hemodynamics by lowering sodium load and supplementing potassium to delay renal function decline. Recent multicenter RCTs and meta-analyses confirm cardiovascular benefits: the SSaSS trial demonstrated 13% reduced cardiovascular event risk with potassium-enriched salt (25% KCl), preventing \~460,000 cardiovascular deaths annually via blood pressure control and \~743,000 non-fatal cardiovascular events (including \~120,000 CKD cases) without significant hyperkalemia-related adverse events. The DECIDESalt trial showed significant blood pressure reductions (SBP: -7.1 mmHg; DBP: -1.9 mmHg) and lower cardiovascular risk with salt substitutes versus regular salt, with post hoc analysis indicating reduced hypertension incidence in normotensive individuals without inducing hypotension. Meta-analyses highlight amplified benefits in high-risk populations and Asian diets via sodium-potassium homeostasis and vascular improvement, with clinically insignificant mild potassium elevation confirming efficacy and safety. Despite these cardiovascular benefits, salt substitutes' renal safety and efficacy in post-nephrectomy patients remain unreported. Thus, the investigators propose this open-label randomized controlled trial to evaluate salt substitutes for postoperative renal protection in kidney tumor patients, establishing evidence-based dietary strategies for renal function preservation.

Therefore, the investigators plan to provide study participants with free salt substitute and standardized salt containers (5g) for one year. Participants will receive a one-month supply of free salt substitute upon hospital discharge. Adherence will be assessed at the one-month follow-up visit via 24-hour urine collection. Based on adherence confirmation, the next two-month supply of free salt substitute will be dispensed, continuing until the three-month follow-up.

This process will be repeated for subsequent phases: Adherence will be evaluated at discharge and each follow-up visit before dispensing the next phase's supply of free salt substitute.To enhance adherence during the extended interval between the 6-month and 12-month postoperative follow-ups: A telemedicine follow-up will be conducted at 9 months post-operation.Adherence will be assessed using a self-administered questionnaire, and the salt substitute will be remotely dispensed upon confirmation.

Non-adherence protocol:

First occurrence: Participants will receive intensive education reinforcing the importance of salt substitute use to improve adherence.

Recurrence: Participants will be discontinued from the study.

03

Conditions studied

  • Kidney Tumors
  • CKD
  • Salt Substitute
  • Nephrectomy
  • eGFR

Keywords

  • kidney tumor
  • CKD
  • Salt substitute
  • nephrectomy
  • eGFR
  • kidney protection
  • kidney function
  • open-label
  • randomized controlled trial
  • Renal function compensation
  • CKD with clinical significance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria:

    1. Voluntary participation with signed from both the primary participant and all cohabiting family members, with commitment to study procedures and follow-up;
    2. Age ≥18 years at enrollment (when signing informed consent), any gender;
    3. Diagnosed kidney tumor patients who underwent radical nephrectomy or partial nephrectomy (no restrictions on surgical approach);
    4. Preoperative >60 ml/min/1.73m² (calculated by CKD-EPI equation);
    5. Serum potassium \<4.8 mmol/L;
    6. Predominantly home-based dietary habits (>90% meals prepared at home, assessed via self-report);
    7. Normal contralateral renal function at screening;
    8. Normal cardiopulmonary and hepatic function:

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded if they meet any of the following:

    1. Participant or cohabiting family members currently using potassium-sparing diuretics or potassium supplements, or prior use of salt substitutes;
    2. Post-discharge \<45 ml/min/1.73m² without significant fluctuation;
    3. Comorbid chronic kidney diseases (e.g., diabetic nephropathy, lupus nephritis);
    4. Preoperative history of urinary tract obstruction;
    5. Cohabiting family member(s) with CKD (eGFR \<45 ml/min/1.73m²);
    6. Planned postoperative nephrotoxic medications (e.g., anti-neoplastic agents, immunotherapy);
    7. Uncontrolled diabetes ( ≥12%);
    8. Uncontrolled hypertension (seated SBP ≥180 mmHg or DBP ≥110 mmHg), symptomatic hypotension (SBP \<90 mmHg), or clinically evident hypovolemia;
    9. Preoperative proteinuria (≥1+ on dipstick);
    10. Severe cardiovascular disease ( Class III-IV), gastrointestinal obstruction, or hyperkalemia history;
    11. \<18.5 kg/m² or >30 kg/m²;
    12. Participation in another clinical trial ≤30 days before randomization or concurrently;
    13. Communication barriers or anticipated non-adherence;
    14. Structural/functional urological abnormalities (e.g., duplicated kidneys, polycystic kidneys, renal artery stenosis, stones, BPH) or indwelling catheters;
    15. Prior radiotherapy/ablation/surgery on the contralateral kidney;
    16. \<6 months (e.g., renal carcinoma).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Salt substitute

    Participants will consume salt substitutes

    Dietary Supplement: Salt substitute

  • No intervention
    Common salt

    Participants will consume Common salt

Interventions

  • Dietary supplementSalt substitute

    Patient consume salt substitutes daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year.Salt substitutes (potassium-enriched low-sodium salt, primarily NaCl and KCl) reduce sodium content versus regular salt

06

What researchers measure

Primary outcomes

  1. Estimated glomerular filtration rate (eGFR)

    Estimated glomerular filtration rate (eGFR) in kidney tumor patients at 12 months after surgery

    Time frame: Postoperative 12 months

Secondary outcomes

  1. Annual eGFR decline rate

    Annual decline rate of eGFR at 12 months postoperatively compared to the "new baseline" post-surgery

    Time frame: Postoperative 12 months

  2. eGFR decline

    Proportion of patients with rapid eGFR decline (\>3 ml/min/1.73m²/year) in each group

    Time frame: Postoperative 12 months

  3. Reduction from baseline

    Decline in eGFR at 12 months postoperatively from the new postoperative baseline (ml/min/1.73m²)

    Time frame: Postoperative 12 months

  4. Incidence of adverse events

    Incidence rate of hyperkalemia (serum potassium ≥5.5 mmol/L) and other adverse events

    Time frame: Postoperative 12 months

  5. Incidence of CKD progression

    The 1-year incidence of CKD progression, which was defined as a worse CKD stage compared to baseline.

    Time frame: Postoperative 12 months

  6. Progression of proteinuria

    Progression of proteinuria (defined as ≥30% increase in urine albumin-to-creatinine ratio from baseline)

    Time frame: Postoperative 12 months

  7. Quality of life questionnaire score

    Kidney Disease Quality of Life 36-Item Short Form Survey;The scoring ranges from 0 to 100, with higher scores indicating better quality of life in patients.

    Time frame: Postoperative 12 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2025 to primary completion in Nov 2026, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jul 2027 → Nov 2026 and completion Dec 2027 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 14, 2025
StartActual
Apr 24, 2025
Primary completionActual
Nov 6, 2026was Jul 2027
CompletionActual
Nov 6, 2026was Dec 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The study was discontinued following a reassessment of the original protocol, which identified the need for substantial modifications to the study design and implementation. The original study was therefore considered unsuitable for continuation
changed Nov 9, 2026
Primary completion
Jul 1, 2027→Nov 6, 2026 (actual)
Nov 9, 2026
Study completion
Dec 31, 2027→Nov 6, 2026 (actual)
Nov 9, 2026
Enrollment
200 (estimated)→93 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Terminated
    Why stopped The study was discontinued following a reassessment of the original protocol, which identified the need for substantial modifications to the study design and implementation. The original study was therefore considered unsuitable for continuation
    Primary completion Jul 1, 2027→Nov 6, 2026 (now actual)
    Study completion Dec 31, 2027→Nov 6, 2026 (now actual)
    Enrollment 200 (estimated)→93 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07062952
Responsible party
Le Qu (Associate chief urologist, Jinling Hospital, China) — Principal investigator
First posted
Jul 14, 2025
Start date
Apr 24, 2025
Primary completion
Nov 6, 2026
Completion
Nov 6, 2026
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salt substitute

Start the discussion